Topical Probiotics Could Aid Wounds Associated With Diabetic Foot Ulcers

Pharmacists are standing at the threshold of a potential shift in wound care as topical probiotics emerge as a promising microbiome-based strategy to combat the multifactorial challenges of diabetic foot ulcers (DFUs). These ulcers represent one of the most serious and costly complications of diabetes, characterized by a high risk of recurrence and frequent infections that often defy current standard-of-care treatments.¹

“DFUs represent one of the most challenging and costly complications of diabetes, with high rates of delayed healing and recurrence despite advances in current therapeutic strategies,” the study authors said. “Within this therapeutic gap, topical probiotics have emerged as a promising, though still experimental, approach.”

Despite advances in surgical debridement, pressure offloading, and infection control, many diabetic wounds remain locked in a chronic nonhealing state due to vascular dysfunction, immune dysregulation, and persistent microbial imbalance. The exploration of topical probiotics seeks to address this gap by restoring the local microbial ecosystem and simultaneously promote tissue repair through antimicrobial, immunomodulatory, and pro-angiogenic mechanisms.

The biological rationale for this approach lies in the unique pathophysiology of the diabetic wound environment. Chronic hyperglycemia disrupts the normal sequence of wound healing—homeostasis, inflammation, proliferation, and remodeling—causing it to stall in a state of self-perpetuating inflammation. In a healthy individual, macrophages transition from a pro-inflammatory M1 phenotype to a reparative M2 phenotype to resolve inflammation and stimulate new vessel formation.^1,2

In patients with diabetes, however, this transition is often impaired, leading to an accumulation of wound debris, excessive production of reactive oxygen species, and the persistence of pathogenic biofilms. This state of dysbiosis, where protective commensal species are replaced by opportunistic pathogens like Staphylococcus aureus and Pseudomonas aeruginosa, creates a hostile microenvironment that further delays granulation tissue formation.¹

Topical probiotics offer a multifaceted therapeutic logic by delivering beneficial microbes directly to the wound bed to counteract these processes. Beyond merely competing with pathogens for space and nutrients, specific probiotic strains—such as Lactiplantibacillus plantarum and Lacticaseibacillus rhamnosus—secrete antimicrobial peptides, organic acids, and hydrogen peroxide that can disrupt established biofilms.

Preclinical studies in diabetic models have shown that these therapies can accelerate wound closure by enhancing collagen deposition and stimulating angiogenesis. For instance, experimental probiotic gels have demonstrated the ability to lower oxidative stress and scavenge excess glucose at the wound site, effectively rebooting the stalled healing process.

For the pharmacist, who is often the most accessible health care professional for diabetic patients, understanding these emerging strategies is increasingly vital. Although current clinical evidence is largely based on small pilot studies and case reports, preliminary findings suggest that topical application of probiotics is well-tolerated and can significantly reduce local bacterial load.^1,3

The pharmacist's role in this evolving landscape extends from medication therapy management to patient education on the importance of glycemic control and daily foot examinations. As medication experts, pharmacists are uniquely positioned to ensure that these microbiome-based interventions, which are currently regarded as experimental adjuncts, are integrated thoughtfully into established DFU management pathways.

Innovation in delivery systems is also paving the way for more sophisticated clinical applications. Researchers are moving beyond simple ointments to develop bioengineered dressings and nano-enabled hydrogels that can improve the stability and therapeutic performance of live microbes or their metabolites, known as postbiotics. Postbiotic strategies, which utilize bacterial lysates or cell-free supernatants, are attracting interest as potentially safer alternatives for high-risk, immunocompromised populations because they provide the beneficial effects of probiotics without the theoretical risk of applying live viable bacteria to compromised tissue. These smart delivery systems can be designed to respond to environmental cues like wound pH or enzyme activity, offering a level of precision-oriented care that could eventually become a staple in the pharmacist’s clinical arsenal.¹

Despite the excitement surrounding these developments, significant hurdles remain before topical probiotics can move from the laboratory to the pharmacy shelf. Large-scale, multicenter randomized controlled trials are still needed to confirm efficacy and clarify safety profiles in high-risk populations, particularly those with severe peripheral arterial disease or chronic kidney disease. Furthermore, the high degree of strain specificity means that the benefits of one probiotic organism cannot be generalized to others, necessitating rigorous characterization and standardization of products. Until such data are available, these therapies should be viewed as complementary rather than substitutive for gold-standard treatments like revascularization and systemic antibiotics for clinically infected ulcers.

“Given that many patients with DFUs present with impaired immunity, vascular compromise, and multiple comorbidities, careful consideration of safety and patient selection is essential, and probiotic-based approaches should currently be regarded as experimental adjuncts rather than established therapies, pending confirmation in larger controlled studies,” the study authors said.

READ MORE: Wound Care Resource Center

Are you ready to elevate your pharmacy practice? Sign up today for our free Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips straight to your inbox.

REFERENCES

1. Çelo E, Dama A, Hasho S, Deda L. Topical Probiotics in Diabetic Wound Healing: Emerging Therapeutic Strategies. Int J Mol Sci. 2026;27(6):2826. Published 2026 Mar 20. doi:10.3390/ijms27062826

2. Rangwala US, Tashrifwala F, Egbert NN, Asif AA. The Potential of Topical Therapy for Diabetic Wounds: A Narrative Review. Cureus. 2023;15(3):e36887. Published 2023 Mar 29. doi:10.7759/cureus.36887

3. Carter C, Renaud A, Holmes M, Berry A, et al. Preventing and treating diabetic foot infections. US Pharm. 2024;49(4):17-20. doi:https://www.uspharmacist.com/article/preventing-and-treating-diabetic-foot-infections